MRTX - Mirati Therapeutics up 9% on pricing $300M upsized equity offering
2023-08-09 04:54:27 ET
More on Mirati Therapeutics
- Mirati Therapeutics: EU Rejection Clouds Krazati's Prospects
- Mirati: The High Stakes Of Krazati's Market Performance Amidst Dwindling Cash (Rating Downgrade)
- Mirati fails to win EU backing for lung cancer therapy
- Mirati tumbles after study failure for cancer drug; Oppenheimer upgrades
- Seeking Alpha’s Quant Rating on Mirati Therapeutics
For further details see:
Mirati Therapeutics up 9% on pricing $300M upsized equity offering